440 research outputs found
Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis
BACKGROUND: Treatment of in-stent restenosis presents a critical
limitation of intracoronary stent implantation. Ionizing radiation has
been shown to decrease neointimal formation within stents in animal models
and in initial clinical trials. We studied the effects of intracoronary
gamma-radiation therapy versus placebo on the clinical and angiographic
outcomes of patients with in-stent restenosis. METHODS AND RESULTS: One
hundred thirty patients with in-stent restenosis underwent successful
coronary intervention and were then blindly randomized to receive either
intracoronary gamma-radiation with (192)Ir (15 Gy) or placebo. Four
independent core laboratories blinded to the treatment protocol analyzed
the angiographic and intravascular ultrasound end points of restenosis.
Procedural success and in-hospital and 30-day complications were similar
among the groups. At 6 months, patients assigned to radiation therapy
required less target lesion revascularization and target vessel
revascularization (9 [13.8%] and 17 [26.2%], respectively) compared with
patients assigned to placebo (41 [63.1%, P=0.0001] and 44 [67.7%,
P=0.0001], respectively). Binary angiographic restenosis was lower in the
irradiated group (19% versus 58% for placebo, P=0.001). Freedom from major
cardiac events was lower in the radiation group (29.2% versus 67.7% for
placebo, P<0.001). CONCLUSIONS: Intracoronary gamma-radiation used as
adjunct therapy for patients with in-stent restenosis significantly
reduces both angiographic and clinical restenosis
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial
BACKGROUND: Restenosis after percutaneous coronary intervention (PCI) is a major problem affecting 15% to 30% of patients after stent placement. No oral agent has shown a beneficial effect on restenosis or on associated major adverse cardiovascular events. In limited trials, the oral agent tranilast has been shown to decrease the frequency of angiographic restenosis after PCI. METHODS AND RESULTS: In this double-blind, randomized, placebo-controlled trial of tranilast (300 and 450 mg BID for 1 or 3 months), 11 484 patients were enrolled. Enrollment and drug were initiated within 4 hours after successful PCI of at least 1 vessel. The primary end point was the first occurrence of death, myocardial infarction, or ischemia-driven target vessel revascularization within 9 months and was 15.8% in the placebo group and 15.5% to 16.1% in the tranilast groups (P=0.77 to 0.81). Myocardial infarction was the only component of major adverse cardiovascular events to show some evidence of a reduction with tranilast (450 mg BID for 3 months): 1.1% versus 1.8% with placebo (P=0.061 for intent-to-treat population). The primary reason for not completing treatment was > or =1 hepatic laboratory test abnormality (11.4% versus 0.2% with placebo, P<0.01). In the angiographic substudy composed of 2018 patients, minimal lumen diameter (MLD) was measured by quantitative coronary angiography. At follow-up, MLD was 1.76+/-0.77 mm in the placebo group, which was not different from MLD in the tranilast groups (1.72 to 1.78+/-0.76 to 80 mm, P=0.49 to 0.89). In a subset of these patients (n=1107), intravascular ultrasound was performed at follow-up. Plaque volume was not different between the placebo and tranilast groups (39.3 versus 37.5 to 46.1 mm(3), respectively; P=0.16 to 0.72). CONCLUSIONS: Tranilast does not improve the quantitative measures of restenosis (angiographic and intravascular ultrasound) or its clinical sequelae
Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years
Objectives: The aim of this study was to investigate the vascular responses and fates of the scaffold after bioresorbable vascular scaffold (BVS) implantation using multimodality imaging. Background: Serial comprehen
The ‘mosaic habitat’ concept in human evolution: past and present
The habitats preferred by hominins and other species are an important theme in palaeoanthropology, and the ‘mosaic habitat’ (also referred to as habitat heterogeneity) has been a central concept in this regard for the last four decades. Here we explore the development of this concept – loosely defined as a range of different habitat types, such as woodlands, riverine forest and savannah within a limited spatial area– in studies of human evolution in the last sixty years or so. We outline the key developments that took place before and around the time when the term ‘mosaic’ came to wider palaeoanthropological attention. To achieve this we used an analysis of the published literature, a study of illustrations of hominin evolution from 1925 onwards and an email survey of senior researchers in palaeoanthropology and related fields. We found that the term mosaic starts to be applied in palaeoanthropological thinking during the 1970’s due to the work of a number of researchers, including Karl Butzer and Glynn Isaac , with the earliest usage we have found of ‘mosaic’ in specific reference to hominin habitats being by Adriaan Kortlandt (1972). While we observe a steady increase in the numbers of publications reporting mosaic palaeohabitats, in keeping with the growing interest and specialisation in various methods of palaeoenvironmental reconstruction, we also note that there is a lack of critical studies that define this habitat, or examine the temporal and spatial scales associated with it. The general consensus within the field is that the concept now requires more detailed definition and study to evaluate its role in human evolution
- …